---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-268135"
form_type: "8-K"
ticker: "CUE"
cik: "0001645460"
company_name: "Cue Biopharma, Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:44:33.368396+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cue Biopharma licenses CUE-100 series to ImmunoScape; receives $15M cash and 40% equity

## Summary
- Collaboration with ImmunoScape to develop 'Seed-and-Boost' TCR-T cell therapy for solid tumors using CUE-100 series.
- Cue Biopharma receives $15M upfront ($10M in Q4 2025, $5M in Nov 2026) and 40% equity stake in ImmunoScape.
- Cue Biopharma eligible for high-single-digit royalties on net sales of any products developed.
- IND-enabling studies on track for 2027 submission; preclinical data shown in pancreatic and ovarian cancer models.
- Cue Biopharma to focus on autoimmune disease programs while oncology development advances with ImmunoScape.

## SEC filing metadata
- accession: 0001193125-25-268135
- form_type: 8-K
- ticker: CUE
- cik: 0001645460
- company_name: Cue Biopharma, Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645460/000119312525268135/0001193125-25-268135-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645460/000119312525268135/cue-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-268135
- JSON: https://secwatch.observer/filing/0001193125-25-268135.json
- Plain text: https://secwatch.observer/filing/0001193125-25-268135.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.